Tribunal rejects refund claim based on assessable value dispute.

The Tribunal upheld the rejection of the refund claim in the appeal against Orders-in-Appeal by the Commr. of Central Excise, Kolkata. The dispute revolved around the assessable value of physician samples distributed by the appellant, with the appellant seeking a refund based on excess duty payment. The appellant's argument for determining value based on the cost of production was refuted as the applicable valuation method was clarified in a Circular issued by the Board and supported by a Bombay High Court decision. Consequently, the appeals were dismissed, affirming the rejection of the refund claim.

---

---

Issues:
- Appeal against Orders-in-Appeal passed by Commr. of Central Excise
- Dispute over assessable value of physician samples
- Appellant's claim for refund based on excess duty payment
- Applicability of Supreme Court ruling on cost of production
- Circular issued by the Board for valuation of physician samples
- Interpretation of Central Excise Valuation Rules for determining value
- Rejection of refund claim and dismissal of appeals

Analysis:
The appeal was filed against Orders-in-Appeal issued by the Commr. of Central Excise, Kolkata, concerning the assessable value of physician samples distributed by the appellant free of cost to medical practitioners during the period from November 2001 to October 2002. The appellant had paid duty on a pro-rata basis, resulting in an excess payment, and sought a refund based on this overpayment. The appellant contended that the value should be determined on the cost of production of goods, citing a Supreme Court ruling in Biochem Pharmaceuticals Industries Ltd. v. Commr. of Central Excise, Vapi. However, it was noted that the Supreme Court's ruling was limited to a specific period preceding the one in question, rendering it inapplicable.

On the other hand, the Revenue argued that a Circular (No. 813/10/2005-CX) issued by the Board clarified that the valuation of physician samples should be done under Rule 4 of the Central Excise Valuation Rules, 2000. This Circular was challenged in a Bombay High Court case, Indian Drugs Manufacturer's Assocn. v. Union of India, where it was held that the valuation of physician samples should be determined under Rule 11 read with Rule 4, not Rule 8. The Court emphasized that Rule 4 is the general rule for valuation, and thus, the valuation of physician samples under Rule 4 was deemed reasonable and consistent with the law.

Consequently, it was established that the value of physician samples during the relevant period should be determined under Rule 4 of the Central Excise Valuation Rules, 2000. As the valuation in the instant case was conducted in accordance with this rule, the refund claim was rejected, leading to the dismissal of both appeals filed by the appellant. The Tribunal found no grounds to interfere with the impugned orders, thereby upholding the decision to sustain the rejection of the refund claim.

---